HM KING MSWATI III SAVED FROM COVID-19, WHO BROUGHT THIS DRUG TO ESWATINI TO SAVE HIS LIFE? ***** The Remdesivir Story — S’swebhu’s Sunday Revelation (Part 1) BY THEMBA MKHOLO MBABANE During the height of the global pandemic, when supply chains were collapsing and life-saving drugs were scarce, Eswatini faced an uphill fight against COVID-19. It has now emerged that local pharmaceutical company Swazipharm/Avapharm under Consul Kareem Ashraff’s directorship played a crucial role in securing the antiviral drug Remdesivir, then hailed worldwide as a “miracle treatment”. The First Dose: A Royal Emergency At the peak of the crisis, a single course of Remdesivir was flown into the Kingdom specifically for His Majesty. The drug was supplied by the Taiwanese Mission to Eswatini. Soon after, several members of the Royal Family and senior government officials required treatment. The Taiwanese Mission subsequently placed an order with Swazipharm/Avapharm for 300 full treatment sets of Remdesivir, which were procured under severe global constraints and later donated to the Government for urgent use. As the pandemic worsened, then Principal Secretary in the Ministry of Health, Dr. Simon Zwane, requested Swazipharm/Avapharm to source a much larger consignment. Against all odds, amid export bans, grounded flights and global shortages, it is said that the company delivered 4 100 treatment sets, each containing 11 vials of Remdesivir. Government only settled payment for the consignment over a year later, during which the supplier reportedly shouldered the financial burden. Research: S’swebhu Video Merging: Clideo

Eswatini’s King Mswati III and the ‘Wonder Drug’ Remdesivir: A Look at Pandemic Diplomacy and Pharmaceutical Supply Chains

When King Mswati III of Eswatini publicly revealed his battle with COVID-19, it sparked not only relief but likewise questions about access to treatment during a time of global scarcity. The story of how the King received Remdesivir, then hailed as a “miracle treatment,” highlights the complex interplay of international relations, pharmaceutical logistics and the role of private companies in navigating a global health crisis.

The Royal Emergency and Taiwan’s Intervention

At the height of the pandemic, securing vital medications like Remdesivir was a monumental challenge. Supply chains were disrupted, export bans were common, and demand far outstripped availability. In Eswatini, the first dose of Remdesivir arrived specifically for King Mswati III, supplied directly by the Taiwanese Mission to Eswatini. This initial delivery underscores the importance of diplomatic ties in securing access to critical healthcare resources.

Swazipharm/Avapharm: A Key Procurement Partner

Following the King’s treatment, the need for Remdesivir extended to members of the Royal Family and senior government officials. The Taiwanese Mission then engaged local pharmaceutical company Swazipharm/Avapharm, under the direction of Consul Kareem Ashraff, to procure additional supplies. Initially, 300 full treatment sets were ordered and donated to the government for urgent use.

As the pandemic worsened, a significantly larger consignment – 4,100 treatment sets, each containing 11 vials of Remdesivir – was requested by the then Principal Secretary in the Ministry of Health, Dr. Simon Zwane. Swazipharm/Avapharm reportedly navigated export bans and logistical hurdles to deliver this crucial supply, despite facing a delay of over a year in receiving payment from the government.

The Global Scramble for Remdesivir: A Reminder of Supply Chain Vulnerabilities

The Eswatini case study mirrors the global experience during the pandemic. Remdesivir, initially developed by Gilead Sciences, faced significant production and distribution challenges. The story highlights the vulnerability of relying on limited suppliers and the critical role of companies capable of navigating complex international procurement processes. The delay in payment to Swazipharm/Avapharm also illustrates the financial strain placed on suppliers during the crisis, potentially impacting future preparedness.

Future Implications: Strengthening Pharmaceutical Resilience

The events in Eswatini offer valuable lessons for future pandemic preparedness. Diversifying pharmaceutical supply chains, fostering stronger international collaborations, and establishing clear payment mechanisms are crucial steps. Investing in local pharmaceutical manufacturing capacity, as seen with Swazipharm/Avapharm’s role, can also enhance a nation’s ability to respond to health emergencies.

the case underscores the importance of transparency in pharmaceutical procurement and the need for equitable access to life-saving medications, regardless of political status.

FAQ

Q: Who initially supplied Remdesivir to King Mswati III?
A: The Taiwanese Mission to Eswatini initially supplied the first course of Remdesivir.

Q: Which company procured the larger consignment of Remdesivir for Eswatini?
A: Swazipharm/Avapharm, under the directorship of Consul Kareem Ashraff, procured the larger consignment.

Q: Was there a delay in payment for the Remdesivir consignment?
A: Yes, the government reportedly settled payment over a year after the consignment was delivered.

Q: What role did international relations play in securing the drug?
A: Strong diplomatic ties with Taiwan were instrumental in securing the initial supply of Remdesivir.

Pro Tip: Building strong relationships with pharmaceutical suppliers and establishing pre-negotiated contracts can help countries secure access to essential medications during a pandemic.

Did you know? Remdesivir was initially developed as a potential treatment for Ebola before being repurposed for COVID-19.

Have you experienced challenges accessing healthcare during a crisis? Share your thoughts in the comments below!

Explore more articles on global health and pandemic preparedness here.